Literature DB >> 22706299

Using protein microarrays to study phosphorylation-mediated signal transduction.

Hong Zhang1, Steven Pelech.   

Abstract

Unraveling the complexity of cell regulatory systems and monitoring their operations under normal and pathological circumstances is one of the major outstanding biomedical challenges. The phosphoproteome has emerged as a rich source of biomarkers for tracking cell signaling and disease, and many of the kinases that phosphorylate proteins represent attractive targets for drug development. Over 100,000 phosphorylation sites distributed in most of the 23,000 proteins encoded by the human genome have already been identified in a non-targeted fashion by mass-spectrometry. Antibody microarrays permit ultra-sensitive, semi-quantitative measurements of the levels of hundreds of target proteins and their phosphorylation in parallel with specimens from cells and tissues. Conversely, reverse-phase protein microarrays (RPPMs) that are printed with crude cell/tissue lysates allow tracking of a target protein with a probing antibody in hundreds to thousands of cell and tissue samples simultaneously. While more than half a million commercial antibodies are available, the identification of highly specific and potent antibodies for use in microarrays remains a major impediment. Antibody cross-reactivity is an issue for both antibody microarrays and RPPMs. The low abundance of signal transduction proteins and their substoichiometric levels of phosphorylation are also problematic. Finally, non-denaturing conditions used with standard antibody microarrays permit protein complexes, which can produce false positives and false negatives. Changes in the level of an interacting protein may be misinterpreted as alterations in the amount of a target protein or its phosphorylation state. It is critical that leads from both types of microarrays are validated by complementary approaches such as immunoblotting and ELISA. More than a hundred reports have appeared in the scientific literature that have benefited from utilization of antibody and protein lysate microarrays. We have highlighted some of the pioneering works in this field and provided recent examples of their successful deployment as tools for broad-based, targeted proteomics research.
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706299     DOI: 10.1016/j.semcdb.2012.05.009

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  9 in total

1.  Integrated Strategies to Gain a Systems-Level View of Dynamic Signaling Networks.

Authors:  Robert H Newman; Jin Zhang
Journal:  Methods Enzymol       Date:  2017-03-07       Impact factor: 1.600

2.  The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia.

Authors:  Terzah M Horton; Fieke W Hoff; Anneke van Dijk; Gaye N Jenkins; Debra Morrison; Teena Bhatla; Laura Hogan; Eleny Romanos-Sirakis; Julia Meyer; William L Carroll; Yihua Qiu; Tao Wang; Qianxing Mo; Steven M Kornblau
Journal:  J Proteomics       Date:  2020-11-16       Impact factor: 4.044

3.  Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.

Authors:  Fares Al-Ejeh; Mariska Miranda; Wei Shi; Peter T Simpson; Sarah Song; Ana Cristina Vargas; Jodi M Saunus; Chanel E Smart; Mythily Mariasegaram; Adrian P Wiegmans; Georgia Chenevix-Trench; Sunil R Lakhani; Kum Kum Khanna
Journal:  Oncotarget       Date:  2014-05-30

4.  Activity Based High-Throughput Screening for Novel O-GlcNAc Transferase Substrates Using a Dynamic Peptide Microarray.

Authors:  Jie Shi; Suhela Sharif; Rob Ruijtenbeek; Roland J Pieters
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

5.  A survival selection strategy for engineering synthetic binding proteins that specifically recognize post-translationally phosphorylated proteins.

Authors:  Bunyarit Meksiriporn; Morgan B Ludwicki; Erin A Stephens; Allen Jiang; Hyeon-Cheol Lee; Dujduan Waraho-Zhmayev; Lutz Kummer; Fabian Brandl; Andreas Plückthun; Matthew P DeLisa
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919

6.  Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.

Authors:  Stephen A Renshaw; Lynne R Prince; Atiqur Rahman; Katherine M Henry; Kimberly D Herman; Alfred Ar Thompson; Hannah M Isles; Claudia Tulotta; David Sammut; Julien Jy Rougeot; Nika Khoshaein; Abigail E Reese; Kathryn Higgins; Caroline Tabor; Ian Sabroe; William J Zuercher; Caroline O Savage; Annemarie H Meijer; Moira Kb Whyte; David H Dockrell
Journal:  Elife       Date:  2019-10-15       Impact factor: 8.140

7.  Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure.

Authors:  Kiriaki Panagopoulos; Sam Cross-Knorr; Christen Dillard; Dionysios Pantazatos; Michael Del Tatto; David Mills; Lisa Goldstein; Joseph Renzulli; Peter Quesenberry; Devasis Chatterjee
Journal:  Mol Cancer       Date:  2013-10-08       Impact factor: 27.401

8.  Phosphokinase antibody arrays on dendron-coated surface.

Authors:  Ju-Won Kwak; Hyobin Jeong; Sun-Ho Han; Youngkyu Kim; Sung Min Son; Inhee Mook-Jung; Daehee Hwang; Joon Won Park
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

9.  Phosphorylation of Connexin36 near the C-terminus switches binding affinities for PDZ-domain and 14-3-3 proteins in vitro.

Authors:  Stephan Tetenborg; Helen Y Wang; Lena Nemitz; Anne Depping; Alexsandra B Espejo; Jaya Aseervatham; Mark T Bedford; Ulrike Janssen-Bienhold; John O'Brien; Karin Dedek
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.